Core Viewpoint - Danah Biotechnology has successfully completed a public offering of 8 million new shares, raising approximately 136.8 million yuan, with a significant oversubscription rate of nearly 4,979 times [1][2]. Group 1: Company Overview - Danah Biotechnology specializes in the early diagnosis of invasive fungal diseases and other pathogen microbiological diagnostic products, recognized as a key "little giant" enterprise supported by the state [2]. - The company's main products include diagnostic reagents categorized into five series based on methodology: enzyme kinetics, enzyme-linked immunosorbent assay (ELISA), immunochromatography, chemiluminescence, and fluorescent quantitative PCR [2]. Group 2: Fund Utilization - The funds raised will be allocated to the construction of a headquarters base in Tianjin, with a total investment of 302 million yuan and a planned capacity of 65.06 million tests [3]. - The new product development project aims to expand product lines based on clinical market needs, focusing on research related to invasive fungal infections, respiratory pathogens, and gynecological infections [3].